Metraipolis › archive › dc_7bab7d2a9bbc
Tolerability and Clinical Benefit Assessment of Continuous Roginolisib Administration in Patients with Cancer including Metastatic Uveal Melanoma — Europe PMC PPR:PPR1135152
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR1135152
- DOI
- 10.21203/rs.3.rs-8048398/v1
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T01:33:05.198Z
- SHA-256 of the archived text
24bf71479ab874d29e58b38096db113ed69a36555b687379de0b86e97775edf5- Stable URL of this page
https://metraipolis.com/documento/dc_7bab7d2a9bbc
How to cite
Tolerability and Clinical Benefit Assessment of Continuous Roginolisib Administration in Patients with Cancer including Metastatic Uveal Melanoma — Europe PMC PPR:PPR1135152 — Europe PMC, https://europepmc.org/article/PPR/PPR1135152 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7bab7d2a9bbc (Metraipolis archive dc_7bab7d2a9bbc, sha256 24bf71479ab874d29e58b38096db113ed69a36555b687379de0b86e97775edf5)
BibTeX
@misc{dc7bab7d2a9bbc,
title = {Tolerability and Clinical Benefit Assessment of Continuous Roginolisib Administration in Patients with Cancer including Metastatic Uveal Melanoma — Europe PMC PPR:PPR1135152},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR1135152},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7bab7d2a9bbc; sha256 24bf71479ab874d29e58b38096db113ed69a36555b687379de0b86e97775edf5},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/PPR/PPR1135152. Agents can read the archived copy with the MCP tool read_document.